Taken together, these data identified Gastrin/CCKBR axis as a critical regulator of intestinal glucose metabolism, and suggest that Gastrin‐SiO2 microspheres, administered orally, may be a viable therapeutic approach in the management of T2D. This evidence concerns the gene CCKBR and type 2 diabetes mellitus.